e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

31.82 +1.02 (+3.31%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Is AbbVie Still a Good Dividend Stock to Buy? ↗

August 08, 2023

Find out if AbbVie can overcome sinking sales of its top-selling product.

Via The Motley Fool

3 Things About Johnson & Johnson Every Smart Investor Knows ↗

July 28, 2023

The company has been a strong value stock but faces big changes this year.

Via The Motley Fool

3 Biotech Stocks You Better Be Buying on Each and Every Dip ↗

July 27, 2023

Biotech companies can bring about life-changing innovations. We've created a list to help you find the best biotech stocks out there.

Via InvestorPlace

12 Analysts Have This to Say About Genmab ↗

July 24, 2023

Via Benzinga

Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

July 21, 2023

From Genmab A/S

Via Business Wire

Where Genmab Stands With Analysts ↗

June 26, 2023

Via Benzinga

Expert Ratings for Genmab ↗

June 06, 2023

Via Benzinga

Recap: Genmab Q1 Earnings ↗

May 10, 2023

Via Benzinga

How To Attend Genmab Q1 2023 Earnings Conference Call ↗

May 08, 2023

Via Benzinga

3 Biotech Stocks That AI is Loving in July ↗

July 12, 2023

As AI becomes a more entrenched aspect of society, investors can lean on these AI recommended biotech stocks with predicted high potential.

Via InvestorPlace

Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators? ↗

July 02, 2023

In May, the FDA approved epcoritamab, developed by AbbVie and Genmab, as a treatment for a type of blood cancer.

Via The Motley Fool

Genmab/AbbVie's Blood Cancer Treatment Shows 82% Response Rate In Pretreated Follicular Lymphoma Patients ↗

June 28, 2023

Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV) have announced topline results from the follicular lymphoma (FL) cohort of the phase 1/2 EPCORE NHL-1 clinical trial evaluating epcoritamab...

Via Benzinga

Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

June 27, 2023

From Genmab

Via Business Wire

Price Over Earnings Overview: Genmab ↗

April 27, 2023

Via Benzinga

Analyst Ratings for Genmab ↗

April 20, 2023

Via Benzinga

P/E Ratio Insights for Genmab ↗

April 11, 2023

Via Benzinga

This Foreboding Sign Looms Over Genmab's Chart ↗

March 31, 2023

Via Benzinga

Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’

June 22, 2023

From Genmab

Via Business Wire

Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023

June 09, 2023

From Genmab

Via Business Wire

What 4 Analyst Ratings Have To Say About Genmab ↗

March 01, 2023

Via Benzinga

Earnings Outlook For Genmab ↗

February 21, 2023

Via Benzinga

Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress

May 25, 2023

From Genmab A/S

Via Business Wire

FDA Approves AbbVie/Genmab's Cancer Drug As First Bispecific Antibody For Type Of Lymphoma In Adult Patients ↗

May 19, 2023

The FDA has approved Epkinly (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)...

Via Benzinga

EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

May 19, 2023

From Genmab A/S

Via Business Wire

Focus On Genmab's Pipeline If Darzalex Arbitration with Janssen Goes Sideways: Analyst ↗

April 24, 2023

Via Benzinga

Genmab Stock Hits 80-Plus Relative Strength Rating Benchmark ↗

April 17, 2023

On Monday, Genmab stock saw its Relative Strength (RS) Rating jump into the 80-plus percentile, rising to 84, up from 80 the day before.

Via Investor's Business Daily

Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

April 17, 2023

From Genmab

Via Business Wire

Alkermes Stock Sees Rising Relative Price Strength ↗

February 17, 2023

The Relative Strength (RS) Rating for Alkermes stock entered a new percentile Friday, with an increase from 79 to 86.

Via Investor's Business Daily

Moderna Stock Getting Closer To Key Technical Benchmark ↗

February 10, 2023

On Friday, biotech Moderna stock received an upgrade to its Relative Strength (RS) Rating, to 72 from 69 a day earlier.

Via Investor's Business Daily

Anavex Life Sciences Stock Shows Improved Price Strength Rating ↗

February 07, 2023

Anavex Life Sciences stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 75.

Via Investor's Business Daily

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy